Interview: Pierre Faraldo – COO, Biopas, Colombia
Chief Operating Officer of Biopas, Pierre Faraldo, depicts the explosive growth the company has been achieving in the past 15 years to become one of Colombia’s success stories, with the…
Address: C Calle 93 B #17–25/49, Piso 5
Bogotá, Colombia
Tel: + 57 1 621 6600
Web: http://www.genzyme.com.co/default_co.asp
Genzyme de Colombia S.A., a subsidiary of Genzyme Corporation, is a growing organization that began its first activities in the country in 1996 through an external consultant for the purpose of registering Ceredase ®, the enzyme for treating Gaucher disease.
Since then, Genzyme de Colombia S.A.’s commitment has been to the continued support of patients, families and health specialists involved with the comprehensive management of lysosomal storage diseases.
It is Genzyme de Colombia S.A.’s mission to collaborate fully for the best quality and life expectancy of all patients in both Colombia and the Andean Pact affected by these diseases and who require on our part a sense of urgency that is present in all our employees.
From the moment Genzyme de Colombia S.A.’s began operations, even before the formal establishment of Genzyme de Colombia SA, the company has been working hard in deepening the knowledge within the medical profession of these diseases, which although of low incidence, significantly impact the patients affected by them.
Support for the medical community and health system in the best knowledge and comprehensive treatment of these diseases resulted in the formal establishment of Genzyme de Colombia S.A. in April 2002.
In July 1998 Genzyme de Colombia S.A. obtained the medical records for Cerezyme ® the first recombinant enzyme approved by the FDA for the treatment of Gaucher disease. In addition Genzyme de Colombia S.A. is currently marketing in Colombia Fabrazyme ® and Aldurazyme ®, the two recombinant enzymes approved by the FDA and the EMEA for the treatment of Fabry disease and MPS1 (Mucopolysaccharidosis 1), respectively.
Similarly, Genzyme de Colombia S.A. has a regional team committed to supporting patients with chronic renal failure and transplantation. We have obtained registration in Colombia for Renagel ® (sevelamer) for the treatment of phosphorus in dialysis patients.
Rare genetic disorders, kidney disease, osteoarthritis, and immunological diseases.
Chief Operating Officer of Biopas, Pierre Faraldo, depicts the explosive growth the company has been achieving in the past 15 years to become one of Colombia’s success stories, with the…
Sunil Dhyani, general manager of IPCA in Colombia, a successful Indian firm continuously launching new molecules, shares his take on the company’s strategy decisions in Colombia, as well as wider…
Thomas Voigt, executive president of the German Chamber of Commerce in Colombia for seven years, discusses the gradual decentralisation of business in Colombia and the increasingly long-term commitment of German…
Francois Léger, recently appointed GM of Servier Colombia discusses his strategy to achieve the company’s ambitious growth plans to launch eight new products within the next three years. You have…
Jaime Calderon, CEO of IETS and with an extensive clinical background and deep understanding of the Colombian healthcare sector, shares IETS’ role in advancing the healthcare landscape while promoting superior…
Pfizer’s country manager and PEH Lead for Colombia & Venezuela, Diego Forero, shares his insights on the Colombian pharmaceutical market, his goals for Pfizer’s Colombian affiliate, and how Colombian operations…
Mariella Soto, QuintilesIMS’ country manager for Colombia, has been working in the pharmaceutical-related industry for over 25 years. She explains how her previous experience as a pharmaceutical executive is helping…
Latin American Regional Head of MSN Labs, one of the most promising generics companies globally, Raman Wattamwar, speaks about the strength of the newly-formed affiliate in Colombia. He highlights Colombia’s…
Cristhian Salamanca, executive director of the Colombia-India Chamber of Commerce and Industry discusses the ties between both countries, the important role of the chamber in attracting Indian companies to Colombia,…
J&J Medical Devices regional VP Mircea Cubillos discusses the long-term vision for J&J in Colombia and Latin America. Moreover, he speaks about the company’s strategy for emerging markets, the importance…
Executive president of ACEMI (La Asociación Colombiana de Empresas de Medicina Integral), Jaime Arias, discusses fostering the constructive participation of all actors in the Colombian healthcare sector and the challenges…
With over a decade as executive director of the Pharmaceutical Chamber of ANDI (The Colombian National Business Association), Rodrigo Arcila Gomez, shares his optimistic insights on the growth of the…
See our Cookie Privacy Policy Here
